he quarter ended December 31, 2010 increased by $57.6 million when compared to the quarter ended December 31, 2009. The growth in revenues is predominately from the increase in the number of patients being prescribed our products. In addition, sales of Remodulin increased by approximately $9.2 million as the result of price increases that went into effect during 2010. Gross margin from sales for the quarters ended December 31, 2010 and 2009 were $146.0 million and $95.1 million, respectively, or 88% of total revenue for both of these quarters. These trends were consistent with the results for the years ended December 31, 2010 and December 31, 2009.
The table below summarizes the components of revenues (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009Cardiopulmonary products:Remodulin
12,8044,27536,3075,789Telemedicine products and services
369,848Operating Expenses. Our operating expenses consist of research and development, selling, general and administrative, and costs of service and product sales.
The table below summarizes research and development expense by major project and non-project components (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009Project and non-project:Cardiopulmonary
10,5736,99734,72224,320Total research and development expense
122,188Cardiopulmonary. The increase in cardiopulmonary project expenses of
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States2
. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States3
. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States4
. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 20085
. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees6
. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States7
. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing8
. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 20099
. United Therapeutics Reports Third Quarter 2008 Financial Results10
. Lilly Contributes $11.1 Million to United Way Annual Campaign11
. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System